Carisoprodol

CAS No:
78-44-4 Category:
  • #LGM Pharma is a Carisoprodol CAS# 78-44-4 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, delivery, purity, and more.
  • #Questions? Call our customer API support number 1-(800)-881-8210.
  • #LGM Pharma offers this active ingredient but not the finished dosage forms.

Product Details:

  • CAS No: 78-44-4
  • AHFC code:
  • Synonyms: Carisoprodate Carisoprodatum Isomeprobamate Isoprotane Isoprothane
  • ATC Code: M03BA02
  • Chemical Formula: C32H44O7
  • Molecular Weight: 260.33
  • Assay/Purity: Typically NLT 98%
  • DrugBank: DB00395 (APRD00417)
  • SMILES: CCCC(C)(COC(N)=O)COC(=O)NC(C)C
  • InChl: OFZCIYFFPZCNJE-UHFFFAOYSA-N
  • PubChem: 2576
  • IUPAC: 2-methyl-2-({[(propan-2-yl)carbamoyl]oxy}methyl)pentyl carbamate

Additional Details

Indication:
For the relief of discomfort associated with acute, painful, musculoskeletal conditions.
Pharmacodynamics:
Carisoprodol is used as a skeletal muscle relaxant. One of its metabolites, meprobamate, is available as an anxiolytic agent.
Mode of Action:
Carisoprodol is a central nervous system depressant that acts as a sedative and skeletal muscle relaxant. Rather than acting directly on skeletal muscle, carisoprodol interrupts neuronal communication within the reticular formation and spinal cord, resulting in sedation and alteration in pain perception. Its exact mechanism of action is not yet known.
Metabolism:
Hepatic. Metabolized in the liver via the cytochrome P450 oxidase isozyme CYP2C19.
Toxicity:
Symptoms of overdose include drowsiness, giddiness, nausea, indigestion, or rash. Other adverse effects attributed to therapeutic use of carisoprodol include dizziness, irritability, insomnia, diplopia, temporary loss of vision, ataxia, weakness, headache, and dysarthria. Non-CNS adverse effects include gastrointestinal complaints, tachycardia, and postural hypotension. Patients sensitive to sulfites or tartrazine may experience wheezing, allergic rashes including erythema multiforme, or anaphylaxis after using some preparations of carisoprodol which contain such additives
General Reference:
Toth PP, Urtis J: Commonly used muscle relaxant therapies for acute low back pain: a review of carisoprodol, cyclobenzaprine hydrochloride, and metaxalone. Clin Ther. 2004 Sep;26(9):1355-67. Pubmed Chou R, Peterson K, Helfand M: Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review. J Pain Symptom Manage. 2004 Aug;28(2):140-75. Pubmed Littrell RA, Hayes LR, Stillner V: Carisoprodol (Soma): a new and cautious perspective on an old agent. South Med J. 1993 Jul;86(7):753-6. Pubmed
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

API’s From Quality Manufacturers:

  • Cost effective materials based on specific requirements
  • Small quantities for initial research and larger development quantities towards product commercialization

 

  • Technical packages, letters of access to filed DMFs
  • Complete assistance in any regulatory filings
  • Top quality GMP certified manufacturers
  • Have necessary regulatory credentials

 

Related YouTube Videos